J&J Loses Around $24B in a Month: How to Play the Stock?

J&J (JNJ) stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and talc-related legal issues are hurting J&J, a lot of this stock price decline could be due to the broader drug/biotech sector decline in the past month. Lower-than-expected sales of Lilly (LLY) and Novo Nordisk’s (NVO) popular diabetes and obesity drugs in the third quarter, guidance cuts, pipeline setbacks ...